- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00951119
Device-guided Breathing Exercises on Blood Pressure in Diabetic Patients (Reperate3)
The Effect of Device-guided Breathing Exercises on Blood Pressure in Diabetic Patients With Hypertension (Resperate-3) A Randomized, Double-blind Controlled Trial
Rationale: Hypertension is an important risk factor of cardiovascular disease, especially in patients with type 2 diabetes mellitus (T2DM). A relatively recent development for the treatment of hypertension is the use of breathing exercises. The investigators' previous studies with a breathing device did not show any positive results. However, these studies and other trials investigating the effects of breathing devices had not a double-blind design. Therefore, the investigators want to perform a randomized, double-blind, controlled trial in a population of T2DM patients.
Objective: To determine the effect of a device slowing breathing (Resperate©) on office systolic blood pressure (SBP) in diabetic patients with treated hypertension with moderate BP control.
Study design: A randomized, double-blind, controlled trial.
Study population: Patients with type 2 diabetes mellitus, over 18 years old and a baseline systolic blood pressure between 140-160 mm Hg.
Intervention: One group receives treatment with a breathing device (Resperate©) and the other group receives treatment with a "control" breathing device. The latter device does not try to alter the breathing pattern.
Main study parameters/endpoints: The effect of the breathing device on SBP is the main study parameter. Secondary endpoints include diastolic blood pressure (DBP) and quality of life.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Zwolle, Holland, 8000 GM
- Isala Clinics
-
Zwolle, Holland, 8000 GM
- Isala Clinics, Diabetes Centre
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- known T2DM,
- over 18 years old,
- known hypertension with a systolic BP (SBP) between 130-170 mm Hg at the previous visit to the internal outpatient department and at the last visit to the internist (which is the same day as baseline measurement) and treated with one or more anti-hypertensive drugs, which have not been changed for the preceding three months. At baseline the SBP should be between 140-160 mm Hg, measured by the investigator.
Exclusion Criteria:
- patients with orthostatic hypotension,
- known heart failure (NYHA III-IV) and/or patients with pulmonary disease (for example asthma, chronic obstructive pulmonary disease and pulmonary fibrosis),
- patients with insufficient knowledge of the Dutch language to understand the requirements of the study,
- additional criteria were hospitalization in the past 3 months, deafness, blindness and cognitive abilities deemed insufficient for operation of a study device.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: resperate device
Resperate© is a device that helps to slow down breathing.
This device can measure the breathing patterns through a breathing sensor mounted on the upper abdomen or chest.
Furthermore, music-like sound patterns can be composed similar to this breathing pattern, which the patient can hear through the headphones of the Resperate©.
By prolonging the expiration, which can be voluntarily used by the user, the frequency of respiration can be slowed down and become more stable (aim"<10 breathings per minute).
|
device-guided breathing exercises
breathing device without slowing of breathing frequency
|
Sham-komparator: control device
Resperate device without slowing of breathing
|
device-guided breathing exercises
breathing device without slowing of breathing frequency
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
The effect of the breathing device on SBP is the main study parameter
Tidsramme: 8 weeks
|
8 weeks
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Secondary endpoints include diastolic blood pressure (DBP) and quality of life.
Tidsramme: 8 weeks
|
8 weeks
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studieleder: HEnk J.G. Bilo, MD, PhD, Professor, FRCP, Diabetes centre, isala clinics
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- Reperate3
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hypertension in Type 2 Diabetes
-
Tampere University HospitalKarolinska Institutet; Tampere University; European UnionTilmelding efter invitationCervikal Intraepitelial Neoplasi Grad 2/3 | Adenocarcinoma in situFinland
-
Forest LaboratoriesAfsluttetTrin 2 Hypertension | Trin 1 HypertensionForenede Stater
-
GE HealthcareAfsluttetIndsaml gennemførlighedsdata og brugerfeedback om brug af en enhed in vivo på gravide frivillige i deres 2. og 3. trimesterForenede Stater
-
Beni-Suef UniversityRekrutteringGruppe 2 Pulmonal hypertensionEgypten
-
Mayo ClinicNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeØstrogenreceptor positiv | Duktalt brystkarcinom in situ | Grad 1 invasivt brystkarcinom | Grad 2 invasivt brystkarcinom | Grad 3 invasivt brystcarcinom | Invasivt duktalt og lobulært karcinom in situ | Slimet brystkarcinom | Tubulært brystkarcinomForenede Stater
-
Gradient Denervation TechnologiesRekrutteringHjertefejl | Gruppe 2 Pulmonal hypertensionForenede Stater
-
NovartisAfsluttet
-
AstraZenecaParexelRekrutteringHjertefejl | Pulmonal hypertension (World Health Organization Group 2)Holland, Spanien, Japan, Tyskland, Østrig, Italien, Kina, Sverige, Det Forenede Kongerige, Forenede Stater, Polen, Tjekkiet, Danmark, Canada
-
Tampere UniversityEuropean Union; Academy of Finland; Cancer Society of FinlandAktiv, ikke rekrutterendeCervikal Intraepitelial Neoplasi Grad 2/3Finland
-
SoniVie Inc.Aktiv, ikke rekrutterendeUkontrolleret trin 2 hypertensionForenede Stater